Anti-HER2 [FRP5]
Catalogue Number: AB03425-1.1-BT-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Shipping Condition: | Blue Ice |
| Unit(s): | 1 mg |
| Host name: | Mouse |
| Clone: | FRP5 |
| Isotype: | IgG1 |
| Immunogen: | The original antibody was generated by immunizing female BALB/c mice with intact SKBR3 human breast tumor cells. |
| Application: | ELISA, FC, IP, Agon |
Additional Text
Gene ID
2064
Gene Name
ERBB2
Uniprot ID
P04626
Purification
Purified
Antibody Clonality
Recombinant Monoclonal
Specificity
CD340; NEU; HER-2; HER-2/neu; ERBB2; MLN 19; NGL; TKR1; erb-b2 receptor tyrosine kinase 2; Receptor tyrosine-protein kinase erbB-2; Metastatic lymph node gene 19 protein; Proto-oncogene Neu; Proto-oncogene c-ErbB-2; Tyrosine kinase-type cell surface receptor HER2
Storage Note
Store at 4⁰C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommed this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20⁰C.
Application Notes
This antibody has been successfully used to immunoprecipitate p185 erbB-2 protein from human SKBR3 breast tumor cell lysates and human erbB-2-transfected mouse HCll R111 cells. Furthermore, the binding of this antibody to surface-expressed HER2 on SKBR3 cells was determined using flow cytometry. Treatment with this antibody led to a rapid increase in the phosphotyrosine content of the erbB-2 protein in various cell lines. The binding of this antibody stimulated the turnover of the erbB-2 protein but did not stimulate DNA synthesis in HCll R111 cells. Therefore, it can be inferred that this antibody acts as a partial ligand agonist (Harwerth et al., 1992; PMID: 1353079). The binding affinity of this antibody for human HER2 was determined using ELISA (Wels et al., 1992; PMID: 1369487). The scFv version of this antibody was used in the generation of scFv(FRP5)-ETA, an antibody-exotoxin recombinant protein and tested for its anti-tumor activity (Harwerth et al., 1993; PMID: 7903153). ScFv(FRP5)-ETA displayed potent antitumoral activity in vitro against a wide range of established and primary human tumor cells, including breast and ovarian carcinomas, squamous cell carcinomas and prostate carcinomas. scFv(FRP5)-ETA also effectively inhibited the in vivo growth of human tumor xenografts and murine and rat tumor cells stably transfected with human c-erbB2 constructs (von Minckwitz et al., 2005; PMID: 16168106).
AB03425-1.1-BT Datasheet
SUPPORT
outstanding technical support
PRODUCT
we offer a full product guarantee
DELIVERY
we offer free delivery to UK universities and non profit organisations